Eric Letouzé
Eric Letouzé
Senior Researcher, INSERM U1162
Verified email at
Cited by
Cited by
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
K Schulze, S Imbeaud, E Letouzé, LB Alexandrov, J Calderaro, ...
Nature genetics 47 (5), 505-511, 2015
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma
C Guichard, G Amaddeo, S Imbeaud, Y Ladeiro, L Pelletier, IB Maad, ...
Nature genetics 44 (6), 694-698, 2012
SDH mutations establish a hypermethylator phenotype in paraganglioma
E Letouzé, C Martinelli, C Loriot, N Burnichon, N Abermil, C Ottolenghi, ...
Cancer cell 23 (6), 739-752, 2013
Integrated genomic characterization of adrenocortical carcinoma
G Assié, E Letouzé, M Fassnacht, A Jouinot, W Luscap, O Barreau, ...
Nature genetics 46 (6), 607-612, 2014
Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification
J Calderaro, G Couchy, S Imbeaud, G Amaddeo, E Letouzé, JF Blanc, ...
Journal of hepatology 67 (4), 727-738, 2017
Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas
JC Nault, S Datta, S Imbeaud, A Franconi, M Mallet, G Couchy, E Letouzé, ...
Nature genetics 47 (10), 1187-1193, 2015
DNA methylation‐based prognosis and epidrivers in hepatocellular carcinoma
A Villanueva, A Portela, S Sayols, C Battiston, Y Hoshida, ...
Hepatology 61 (6), 1945-1956, 2015
EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype
S Rebouissou, I Bernard-Pierrot, A de Reyniès, ML Lepage, C Krucker, ...
Science translational medicine 6 (244), 244ra91-244ra91, 2014
Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation
JC Nault, G Couchy, C Balabaud, G Morcrette, S Caruso, JF Blanc, ...
Gastroenterology 152 (4), 880-894. e6, 2017
Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation
C Pilati, E Letouzé, JC Nault, S Imbeaud, A Boulai, J Calderaro, ...
Cancer cell 25 (4), 428-441, 2014
Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis
E Letouzé, J Shinde, V Renault, G Couchy, JF Blanc, E Tubacher, ...
Nature communications 8 (1), 1315, 2017
Genotype‐phenotype correlation of CTNNB1 mutations reveals different ß‐catenin activity associated with liver tumor progression
S Rebouissou, A Franconi, J Calderaro, E Letouzé, S Imbeaud, C Pilati, ...
Hepatology 64 (6), 2047-2061, 2016
Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas
LJ Castro-Vega, E Letouzé, N Burnichon, A Buffet, PH Disderot, E Khalifa, ...
Nature communications 6 (1), 6044, 2015
Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma
N Burnichon, A Buffet, B Parfait, E Letouzé, I Laurendeau, C Loriot, ...
Human molecular genetics 21 (26), 5397-5405, 2012
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma
J Hadoux, J Favier, JY Scoazec, S Leboulleux, A Al Ghuzlan, ...
International Journal of Cancer 135 (11), 2711-2720, 2014
Oncometabolites‐driven tumorigenesis: from genetics to targeted therapy
A Morin, E Letouzé, AP Gimenez‐Roqueplo, J Favier
International journal of cancer 135 (10), 2237-2248, 2014
Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas
C Pilati, J Shinde, LB Alexandrov, G Assié, T André, Z Hélias‐Rodzewicz, ...
The Journal of pathology 242 (1), 10-15, 2017
Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response
S Caruso, AL Calatayud, J Pilet, T La Bella, S Rekik, S Imbeaud, ...
Gastroenterology 157 (3), 760-776, 2019
Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma
JC Nault, Y Martin, S Caruso, TZ Hirsch, Q Bayard, J Calderaro, C Charpy, ...
Hepatology 71 (1), 164-182, 2020
Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress
Q Bayard, L Meunier, C Peneau, V Renault, J Shinde, JC Nault, I Mami, ...
Nature Communications 9 (1), 5235, 2018
The system can't perform the operation now. Try again later.
Articles 1–20